CFO buys 3,000 AVITA Medical (RCEL) shares in open trade

Rhea-AI Filing Summary

AVITA Medical, Inc. Chief Financial Officer David D. O'Toole reported an open-market purchase of 3,000 shares of common stock on February 19, 2026 at $4.15 per share. Following this buy, his directly held stake increased to 140,127 shares, which includes unvested restricted stock units.

Insider Trade Summary

Net Buyer: 3,000 shares ($12,450)

Net Buy 1 txn

Insider O'Toole David D

Role CFO

Bought 3,000 shs ($12K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	3,000	$4.15	$12K

Holdings After Transaction: Common Stock — 140,127 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Toole David D

(Last) (First) (Middle)

28159 AVENUE STANFORD

SUITE 220 - AVITA MEDICAL

(Street)

VALENCIA CA 91355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AVITA Medical, Inc. [ RCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		P		3,000	A	$4.15	140,127(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes unvested RSUs.

	David O'Toole	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AVITA Medical (RCEL) report on this Form 4?

AVITA Medical reported that CFO David D. O'Toole bought 3,000 shares of common stock in an open-market transaction. The purchase occurred at a price of $4.15 per share, indicating an increase in his personal equity stake in the company.

How many AVITA Medical (RCEL) shares does the CFO own after this transaction?

After the reported trade, CFO David D. O'Toole directly holds 140,127 AVITA Medical common shares. This figure includes unvested restricted stock units, meaning part of the reported ownership represents equity awards that are subject to vesting conditions over time.

Was the AVITA Medical (RCEL) CFO’s Form 4 transaction a purchase or a sale?

The transaction was a purchase. The Form 4 shows CFO David D. O'Toole executed an open-market buy of 3,000 shares of AVITA Medical common stock, classified under transaction code “P,” which denotes a purchase in the open market or private transaction.

What price did the AVITA Medical (RCEL) CFO pay per share in this trade?

The CFO paid $4.15 per share for the 3,000 AVITA Medical common shares. This reported transaction price reflects the cost per share in the open-market purchase, as disclosed in the Form 4’s non-derivative transaction details for the February 19, 2026 trade.

What does “includes unvested RSUs” mean in the AVITA Medical (RCEL) Form 4?

“Includes unvested RSUs” means the 140,127 shares reported as held by the CFO count both currently vested shares and restricted stock units not yet vested. These RSUs are equity awards that convert into shares over time, subject to vesting requirements and conditions.